ABSTRACT I-Isoproterenol was covalently coupled via an azo linkage to soluble copolypeptides of molecular weight 1500 and 10,000 containing an aromatic amine. The polymeric azo-isoproterenol derivatives were purified by gel chromatography which reduced contamination by the parent isoproterenol to undetectable levels (i.e., less than 0.01%) and by 8- 1009 levels in cardiac muscle with the immobilized drugs (6) which, by extrapolation, indicate that the drug could be acting in a covalently bound form.
tude, respectively, of the EDs0 of 1-isoproterenol. The responses cannot be attributed to free isoproterenol because this drug could not be detected in our preparations. Neither can the observed biological activity be attributed to 6-aminoisoproterenol, since this compound's dose-response is shifted 3 orders of magnitude to the right of i-iso roterenol and 1-2 orders of magnitude to the right of the po1'meric derivatives. Inotropic response decay times in isolated cat papillary muscles following washouts indicate that the polymer-bund drug does not diffuse into the muscle tissues. We feel that our findings demonstrate that under controlled conditions the catecholamines can retain biological activity while covalently bound to a polymeric support. Since the earliest reports concerning the immobilization of enzymes onto insoluble matrices by Katchalski (2) (3) (4) . Because large molecules such as enzymes may be attached to the matrix by more than one covalent bond, the biological activity of the covalently bound species is not in question. However, the evidence is by no means so clear-cut for small molecules which may be biologically active at extremely low concentrations and which are often attached to the matrix by only one covalent bond per molecule. In such cases, the concept of a covalently immobilized drug may be limited by the chemical stability of both the bond linking the drug to the matrix and also the chemical stability of the matrix itself (5) . In the case of glass beadimmobilized catecholamines, for instance, it has.proved to be almost impossible to eliminate completely the possibility of a minute leakage of covalently or noncovalently bound biogenic amine into a micro-volume at the bead-tissue interface as the cause of the observed biological effects (5). However, numerous differences in the mode of action of the parent and immobilized catecholamines have been demonstrated by, for example, lack of changes in the cyclic AMP Abbreviations: ED5o, mean effective dose, the concentration of drug required to produce 50% of the maximal response; Mr, molecular weight. * To whom reprint requests should be addressed. 1009 levels in cardiac muscle with the immobilized drugs (6) which, by extrapolation, indicate that the drug could be acting in a covalently bound form.
Despite such evidence, we feel that the studies published to date have not conclusively demonstrated that the biological activity of "immobilized", small, biologically active molecules is due solely to the covalently bound species. The approach of covalently attaching biologically active molecules, such as analogs of the luteinizing hormone releasing factor, to water-soluble, synthetic polymers (7) has been extended to determine if catecholamines and other small molecules can retain their biological activity while covalently "immobilized" on polymeric supports. We have undertaken the synthesis of a series of water-soluble polypeptides to which the catecholamines are covalently attached via an azo linkage. The polymer-substituted catecholamines have been subjected to an exhaustive series of tests in order to eliminate the possibility that noncovalently attached molecules contribute to the biological activity of these new agents. We feel that our results presented here represent a rigorous proof of biological activity of a drug covalently immobilized on a supporting matrix.
MATERIALS AND METHODS
y-Benzyl glutamic acid and dibenzyl glutamate hydrochloride were obtained from Bachem Fine Chemicals, Inc. and the Fox Chemical Co., respectively. p-Nitro-L-phenylalanine was prepared by the literature procedure (8), mp 238-2390 (literature mp 238-241'). I-Isoproterenol hydrochloride and d,l- [7-3H] isoproterenol were obtained from the Sigma Chemical Co. and New England Nuclear, respectively. All other materials were of analytical or reagent grade and were used without further purification, except for dioxane and 3-amino-l-propanol (Aldrich) which were dried over molecular sieves (Linde 4A) before use. Viscosity measurements were made in water at 25°4 0.10 using a Cannon-Ubbelohde viscometer with a solvent efflux time of 234.4 + 0.1 sec. Equilibrium ultracentrifugation molecular weight determinations were made at 300 in water by the method of Yphantis (9) with a Beckman Spinco model E ultracentrifuge. Thin-layer chromatograms were run as previously described (10) using precoated glass silica gel plates (Brinkmann) developed in a butanol:acetic acid:water (66: 17:17) system. RF values were: 1-isoproterenol, 0.56; and 6-amino-l-isoproterenol, 0.27.
Synthesis of Copolypeptides of Hydroxypropylglutamine with p-Aminophenylalanine. y-Benzyl-L-glutamic acid N-carboxy anhydride (11) (1.61 g; 6 mmol) and p-nitro-Lphenylalanine N-carboxy anhydride (12) (0.35 g; 1.5 mmol) were copolymerized at room temperature in dry dioxane (25 ml) using dibenzyl glutamate as initiator, with initial anhydride-to-initiator mole ratios (A/I) of 5 and 50. When polymerization was complete, each mixture was diluted with an approximately equal volume of anhydrous 3-amino-1-propanol (13) and stirred overnight at room temperature. Precipitation from a large volume of dichloromethane resulted in sticky solids which were reduced by the following methods: (a) the lower rriolecular-weight polymer (A/I = 5) was dissolved in water (50 ml) and hydrogenated at low pressure using 10% palladium on charcoal as catalyst. (b) A solution of the higher molecular-weight sample (A/I = 50) in 0.5 M NaHCO3 (25 ml) was reduced by adding solid sodium dithionite (1.25 g) and stirring the mixture at 500 for 1 hr. The lower molecular-weight polymer was fractionated by gel chromatography on Bio-Gel P-2 (see Fig. 2 ) using the peak fractions with an intrinsic viscosity [X] = 0.035 in water. The molecular weight of this sample was estimated from ebullioscopic determinations (Huffman Laboratories, Inc.) to be approximately 1500. The higher molecular-weight polymer was purified free of low-molecular-weight material by exhaustive dialysis using a Spectrapor 3 membrane (Spectrum Medical Industries, Inc., molecular weight cut-off approximately 3500). The intrinsic viscosity of this sample was 0.077 (in water), and its molecular weight was calculated to be 9600 (from ultracentrifugation measurements).
Synthesis of Polymeric Catecholamine Derivatives. The copolypeptides (100 mg), dissolved in 0.25 M HC1 (2 ml), were cooled to 00 and diazotized by treating with an icecold 0.5 M NaNO2 solution (0.5 ml). After 15 min, a cold solution of l-[3H]isoproterenol (specific activity = 1 mCi/ mmol; 50 mg) in 0.25 M sodium phosphate buffer, pH 7 (1 ml) was added, the solution was titrated to pH 7.0, and the coupling reaction was allowed to go overnight in the dark at 40. The products were purified free of low-molecularweight material by gel chromatography (see Fig. 2 ), and rechromatographed at least twice more, in order to remove final traces of free catecholamine before assaying for biological activity.
Simulation of Muscle Bath Conditions. The purified high-molecular-weight (10,000) polymeric isoproterenol derivative (80 mg) was dissolved in Krebs solution (10 ml) . This solution was oxygenated with a 95% 02, 5% C02 mixture in the dark for 15 min at 370 and immediately chromatographed on Bio-Gel P-2 as described.
RESULTS
Purification of Polymeric Catecholamine Derivatives. The proposed structure of the polymeric azo-catecholamine derivatives is shown in Fig. 1 . The exact structure cannot be given because the polymer is a random one. Since the diazotized aminophenylalanine residues are not fully substituted we assume the remainder to be hydrolyzed to tyrosyl residues during work-up of the derivatives. The column elution profiles for the lower molecular-weight polymeric azo-isoproterenol derivative are illustrated in the upper portion of Fig. 2 . The products of the diazotization reaction mixture were separated by this method and subsequently identified by thin-layer chromatography. The first column purification of this derivative ( Fig. 2-1 ) resulted in four peaks assigned to the polymeric derivative, an unassigned minor peak, 6-aminoisoproterenol, and free isoproterenol. It is interesting to note that isoproterenol and its 6-amino derivative were separated by this method. Fig. 2-2 represents the third subsequent purification of the polymeric isoproterenol derivative peak. The most significant point of this purification is the re- Proposed structure of polymeric azo-isoproterenol derivatives. The polymer is a random copolymer of hydroxylpropylglutamine and p-aminophenylalanine. The ratio of hydroxylpropylglutamine to p-aminophenylalanine is 4:1. There is a 2.5% (by weight) incorporation of isoproterenol into the polymer. Since the diazotized aminophenylalanine residues are not fully substituted, we assume the remainder are hydrolyzed to tyrosyl residues. duction of contamination by the parent l-isoproterenol to undetectable levels (i.e., less than 0.01%). A small but recurrent contamination by 6-aminoisoproterenol was present at each column purification, probably due to photolysis of the azo linkage of the catecholamine to the polymer during storage and handling. This contamination by the 6-amino derivative represented less than 0.4% of the polymeric catecholamine peak in each case.
The purification of the higher molecular-weight (10,000) polymeric catecholamine derivative was essentially identical to that of the 1500-molecular-weight derivative described above. The soluble, parent isoproterenol peak, 6-aminoisoproterenol, and polymeric isoproterenol peaks were in the identical fractions to those observed for the lowermolecularweight derivative (Fig. 2-3 ). Subsequent gel chromatography of this higher molecular-weight derivative (Fig. 2-4) revealed no detectable l-isoproterenol, indicating less than 0.01% contamination by this amine. As in the case of the lower molecular-weight derivative, 6-aminoisoproterenol was detectable at each purification step, although the degree of contamination was always less than 0.05% of the polymerbound isoproterenol.
Thin-layer chromatography of the polymeric isoproterenol derivative peaks from the columns revealed no detectable free isoproterenol or its 6-amino derivative when the plates were scanned using a radiochromatograph (limits of sensitivity: 0.4%).
These polymeric isoproterenol derivatives proved very stable to storage at -15°. Figs. 2-2 and 2-4 represent chromatography after approximately 3 months' storage at this temperature. Since no parent isoproterenol was detectable in three subsequent purifications by gel chromatography (i.e., less than 0.01%) and since the 6-amino catecholamine contamination on any column was less than 0.4%, these values represent the maximum levels of contamination of the polymeric isoproterenol derivative by free drug molecules.
Biological Characterization of Polymeric Catecholamine Derivatives. The two polymeric isoproterenol derivatives were tested for biological activity both immediately following their final gel chromatography, and also after lyophilization. The results were identical in each case. The Purification of polymeric azo-isoproterenol derivatives. Sections 1 and 3 represent the elution profiles for the separation of the products from the coupling reactions of the 1500 and 10,000 Mr derivative, respectively. Peak assignment by thin-layer chromatography (Materials and Methods) indicates: the polymeric isoproterenol derivatives (A); an unassigned lower molecular-weight polymeric peak (B); 6-amino-l-isoproterenol (C); and l-isoproterenol (D). Sections 2 and 4 represent the third subsequent column purifications of the respective polymer peaks, with inserts illustrating peaks (C) and (D) at 100-fold increase in sensitivity. Gel chromatography was performed on a BioGel P-2 (Bio-Rad) column (2.7 X 85 cm) at 40, using 1 mM ammonium bicarbonate as eluent. Fractions (12.5 ml) were monitored either by UV absorption at 236 nm (polymers alone) or by radioactivity (catecholamine derivatives); isoproterenol-containing peaks were lyophilized in the dark. polymeric catecholamine derivatives both produced positive chronotropic responses in a dose-related manner when injected into isolated perfused guinea pig hearts. The log doseresponse relationships for the two polymeric derivatives are compared with l-isoproterenol, 6-amino-l-isoproterenol, and l-epinephrine in Fig. 3 . The responses are plotted as a function of the total number of moles of isoproterenol added, determined using radiolabeled catecholamines.
The mean effective dose (ED5o) for l-isoproterenol is 1.4 X 10-11 mol. The dose-response for the lower molecularweight (1500) polymeric isoproterenol derivative is shifted to the right of that for isoproterenol by 1.3 orders of magnitude, with an EDso of 2.8 X 10-10 mol. The dose-response relationship for the higher molecular-weight (10,000) derivative is shifted slightly further to the right with an ED5o of 1.4 X 10-9 mol. Thus, the polymeric isoproterenol derivatives, while less active than the parent isoproterenol, are considerably more active than both 6-aminoisoproterenol and l-epinephrine. The dose-response relationship for 6-aminoisoproterenol (Fig. 3) indicates an ED50 of 2.2 X 10-8 mol which is very similar to that reported previously for this derivative (10) .
The ED5o for l-epinephrine is calculated as 2.0 X 10-9 mol.
The f3-adrenergic antagonist dl-propranolol (5 X 10-7 M) inhibits the chronotropic action of the polymeric isoproterenol (10,000 Mr) derivative in an apparent competitive manBiochemistry: Verlander et al. (14) . The perfusates from the guinea pig hearts were collected within seconds of drug testing and immediately subjected to thin-layer chromatography. No 6-aminoisoproterenol or isoproterenol was detectable by this means. The perfusate was also concentrated more than 1000-fold by lyophilization and re-subjected to thin-layer chromatography, after which no detectable contaminants were found either visually or using radioscanning.
Diffusion Studies with Polymeric Catecholamine Derivatives. In previous studies with immobilized catecholamines a differential action of catecholamine molecules has been suggested based on limits of diffusion and sites of action (15) and it has been calculated that within 10 min of adding soluble isoproterenol (Mr = 250) to the bathing solution of an isolated cat papillary muscle the drug will have approached equilibrium in the inner core of the muscle by diffusion (15) . In contrast, the diffusion of a 10,000 Mr polymeric derivative will be substantially reduced. Because the response onset in cardiac muscle involves catecholamineinduced propagation (6) the drug washout times were studied, comparing the free isoproterenol to the high-molecularweight polymeric isoproterenol derivative. The results were dramatic. Following a single washout of the polymeric derivative, after a 10 min incubation, the force of contraction returned to control levels, usually within 2 min. In contrast a dose of free isoproterenol which produces an essentially identical response took on average over 20 min to return to control levels following-a single washout. As a control soluble isoproterenol was added together with unsubstituted 10,000 Mr polymer. The resulting washout time was essentially identical to that for free isoproterenol. These results are summarized in Table 1 .
Subjecting the high-molecular-weight polymeric derivative to simulated muscle bath conditions (Materials and Methods) resulted in no detectable isoproterenol and less than 0.4% 6-aminoisoproterenol. From these results we conclude that insufficient free drug was produced during the course of the assay to produce the observed biological activity.
DISCUSSION
The dose-response relationships illustrated in Fig. 3 indicate that the responses observed for the polymeric isoproterenol derivatives cannot be due to contamination by 6-aminoisoproterenol, since 300 and 500% contaminations of this derivative would be required to explain the activity we observe for the 10,000-and 1500-molecular-weight polymeric isoproterenol derivatives, respectively. Because of the shift in the dose-responses to the right of the parent l-isoproterenol it was critical to be able to rule out the presence of traces of this compound. A contamination of greater than 5% and 1% of l-isoproterenol would be required to explain the respective dose-responses of the 1500 and 10,000 Mr derivatives. Gel chromatography (Fig. 2) and thin-layer chromatography have indicated that the highest possible contamination by l-isoproterenol is less than 0.01%, which is at least 1.5-2 orders of magnitude less than the minimum amount required to explain our results. The chromatography immediately prior and subsequent to biological testing indicates that no detectable free l-isoproterenol was present in our preparations. We feel that our controls more than adequately rule out the possibility of contamination by free isoproterenol or 6-amino-isoproterenol explaining our results.
The drug washout and response decay experiments (Table  1) represent both a unique control experiment and also an example of an area where polymeric drug derivatives may find great utility. Our results show that the higher molecular-weight (10,000) polymeric isoproterenol derivative can be removed from the muscle baths with one washing, resulting in an immediate response decay to control levels. This is in sharp contrast to the results obtained with soluble isoproterenol (Table 1) where, following one bath change, there is a very slow response decay to control levels. We feel that these results can be explained in terms of the different diffusion rates of the two types of drug. These observations are a further indication that we are not dealing with a "dissociated" species of isoproterenol. If the observed responses were due to an isoproterenol contaminant the washout differentials would be identical to that obtained with a mixture of soluble isoproterenol and unsubstituted polymer ( Table 1) .
The structure-activity relationships of substituted catecholamines further support our contention of a biologically active, covalently coupled polymeric isoproterenol deriva-Proc. Nat. Acad. Sci. USA 73 (1976) 1013 Isolated right ventricular cat papillary muscles were prepared as described (6, 17) . They were subjected to the indicated compounds for 10 or 40 min. The papillary muscle bath was drained, refilled with fresh oxygenated Krebs solution, pre-warmed to 300, drained, and again refilled with fresh Krebs solution. The force of contraction was monitored until the control inotropic state was obtained. The dose of soluble isoproterenol was chosen to match the inotropic response obtained with the polymer-immobilized isoproterenol. The papillary muscles were maintained at 300 and stimulated to contract at 12 contractions per minute.
* Mean + SEM; n = number of experiments.
tive. It has previously been shown that azo substitution occurs at the 6-position on the catechol ring and that soluble azo-substituted catecholamines possess considerable activity (10) . In contrast, norepinephrine bound via an amide linkage from the ethanolamine sidechain to either glass or Sepharose possesses no detectable biological activity (16, 17) . We conclude from the present studies that the polymeric azo-isoproterenol derivatives are exerting their activity in the "immobilized", or conjugate form. The mechanism of action of these agents may be quite different from insoluble, immobilized catecholamines (5). However, our present findings, which indicate that drugs and hormones can retain biological activity while covalently bound to soluble polymers, suggest that insoluble, covalently bound drugs may also react directly in biological systems.
We feel that polymeric drugs, when properly prepared and rigorously purified as we have described, will have broad applications in pharmacology, biochemistry, and medicine.
